TBPH Theravance Biopharma, Inc. — QuoTrend

Analyst Ratings

Date	Action	Analyst	Rating	Target
Mar-05-26	Downgrade	Oppenheimer	Outperform → Perform
Mar-04-26	Reiterated	B.Riley Financial		$14
Mar-04-26	Downgrade	B. Riley Securities	Buy → Neutral
Dec-03-25	Initiated	Oppenheimer	Outperform	$27
Nov-26-25	Reiterated	BTIG	Buy	$21 → $40
Nov-13-24	Reiterated	Leerink Partners	Market Perform	$14 → $10
Aug-06-24	Reiterated	H.C. Wainwright		$20 → $15
Aug-06-24	Downgrade	Leerink Partners	Outperform → Market Perform
Apr-12-24	Reiterated	BTIG		$21
Nov-17-22	Reiterated	Leerink Partners		$14

Financial Statements

DataTimeframe

Line Item (USD, M)		TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue		110	107	64	Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A		21	6	38
Gross Profit		88	102	27
Selling, General and Administrative Excl. Other		38	74	69
Research and Development		31	37	38
Other Operating Expense		19	4	-33
Operating Income		1	-13	-47
Interest Expense		3	2	3
Unusual Expense		—	—	—
Non-Operating Income (Expense)		-139	-145	-5
Net Income Before Taxes		137	129	-45
Income Taxes		21	23	12
Consolidated Net Income		115	106	-56
Net Income From Continuing Operations		115	106	-56
Net Income		115	106	-56
EPS (Recurring)		2.26	2.10	-1.15
EPS (Basic, Before Extraordinaries)		2.26	2.10	-1.15
EPS (Diluted)		2.20	2.06	-1.15
EBITDA		142	137	-38
Other After Tax Adjustments		—	—	—
Stock Option Compensation Expense		—	—	—
Price To Earnings Ratio		7.54	9.08	—
Price To Sales Ratio		7.69	8.74	—
Gross Margin		80.00	95.33	42.19
Operating Margin		0.91	-12.15	-73.44
Net Margin		104.55	99.07	-87.50
Shares Outstanding		51	50	49
Market Capitalization		846	936	—
Operating Lease Expense		—	—	—

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jun 15 '26	Sale	16.39	13,314	218,167	232,457	Jun 17 12:00 AM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Mar 16 '26	Sale	13.96	31,067	433,637	232,699	Mar 18 12:00 AM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Dec 03 '25	Sale	18.75	31,067	582,501	277,695	Dec 05 12:00 AM
BROSHY ERAN	Director	Nov 26 '25	Sale	20.00	29,501	590,020	44,703	Dec 01 12:00 AM
BROSHY ERAN	Director	Nov 26 '25	Option Exercise	10.15	14,000	142,100	81,749	Dec 01 12:00 AM
BROSHY ERAN	Director	Nov 11 '25	Sale	18.05	104,000	1,877,500	46,204	Nov 14 12:00 AM
BROSHY ERAN	Director	Nov 11 '25	Option Exercise	10.15	14,000	142,100	107,878	Nov 13 12:00 AM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jul 14 '25	Sale	11.39	10,000	113,870	326,918	Jul 16 12:00 AM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jun 02 '25	Sale	11.00	24,000	264,000	336,918	Jun 04 12:00 AM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Apr 21 '25	Sale	9.00	4,000	36,000	370,038	Apr 23 12:00 AM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jan 21 '25	Sale	9.00	4,000	36,000	309,565	Jan 23 12:00 AM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Nov 11 '24	Sale	9.00	4,000	36,000	322,743	Nov 13 12:00 AM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jul 10 '24	Sale	9.00	4,000	36,000	335,965	Jul 12 12:00 AM
Samaha Eli	10% Owner	May 01 '24	Buy	8.75	1,499,124	13,117,335	8,511,350	May 03 12:00 AM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Feb 22 '24	Sale	8.71	1,254	10,922	311,733	Feb 22 12:00 AM